Keyword: Pfizer

Spark Therapeutics logo on labcoat

Spark Therapeutics

After launching in late 2013 with $50 million and a clutch of gene therapies out of Children’s Hospital of Philadelphia, Spark Therapeutics hit the gas. It picked up another $73 million and a Big Pharma partner en route to its upsized IPO in 2015.

Lilly gets positive abemaciclib phase 3 data, plots 2017 NDA

Eli Lilly was hit earlier this month when rival Novartis became the second, after front-runner Pfizer, to gain FDA approval for its CDK 4/6 inhibitor Kisqali (ribociclib), but a readout from its new phase 3 data has buoyed the Big Pharma nonetheless, as it plots an NDA in Q2.